• Chimerix Inc., of Durham, N.C., published results of a Phase II study of brincidofovir (CMX001) for cytomegalovirus (CMV) in hematopoietic cell transplant (HCT) recipients in the Sept. 26, 2013, issue of the New England Journal of Medicine. The drug has shown broad-spectrum antiviral activity against double-stranded DNA viruses, including CMV.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter